Indications & Scoring - The Waiting Game
-
Indications for Transplant
- Acute Liver Failure: Fulminant viral hepatitis (A, B), drug-induced (e.g., Acetaminophen), Wilson's disease.
- Chronic Liver Disease: Decompensated cirrhosis from any cause (HCV, HBV, NAFLD, alcohol), Hepatocellular Carcinoma (HCC) within Milan criteria.
-
MELD Score: Prioritizes Allocation
- Calculates 3-month mortality risk. Formula: $MELD = 3.78 imes ext{ln[Bilirubin]} + 11.2 imes ext{ln[INR]} + 9.57 imes ext{ln[Creatinine]} + 6.43$
- 📌 Mnemonic: I Bleed Chestnuts (INR, Bilirubin, Creatinine).
-
Absolute Contraindications
- Severe, irreversible cardiopulmonary disease.
- Active extrahepatic malignancy.
- Ongoing alcohol or illicit substance abuse.
⭐ Patients with a MELD score ≥ 15 are typically listed. MELD-Na is a common variant, adding sodium for better prognostication in hyponatremia.

Donor & Surgery - The Main Event
- Deceased Donor (DDLT): Whole organ from a deceased donor; longer wait times.
- Living Donor (LDLT): Partial graft (e.g., right lobe) from a living donor; technically complex.

- Key Early Complications:
- Hepatic Artery Thrombosis (HAT): Most common vascular complication.
- Portal Vein Thrombosis
- Biliary leaks & strictures
⭐ HAT is a surgical emergency, often presenting with graft dysfunction and requiring urgent re-transplantation.
Rejection Types - The Body Fights Back
| Type | Onset | Pathophysiology | Histology Findings |
|---|---|---|---|
| Hyperacute | Minutes to hours | Pre-formed anti-donor Abs | Vascular thrombosis, neutrophilic infiltrate |
| Acute | Days to weeks (<6 mo) | T-cell mediated injury | Portal lymphocytic infiltrate, endothelitis |
| Chronic | Months to years (>6 mo) | Mixed cellular & humoral | Vanishing bile duct syndrome, progressive fibrosis |
⭐ Acute rejection is the most common type, typically occurring within the first few months post-transplant; it is usually reversible with immunosuppressive therapy.
Immunosuppression - Taming the Guards
- A multi-drug regimen prevents rejection by targeting different immune pathways, balancing efficacy with toxicity.
| Drug Class | Drugs | Key Adverse Effects |
|---|---|---|
| Calcineurin Inhibitors | Tacrolimus, Cyclosporine | Nephrotoxicity, neurotoxicity (tremor), HTN, ↑K⁺ |
| Antimetabolites | Mycophenolate Mofetil | GI distress (diarrhea), bone marrow suppression |
| mTOR Inhibitors | Sirolimus, Everolimus | Hyperlipidemia, delayed wound healing, stomatitis |
| Corticosteroids | Prednisone | Hyperglycemia, osteoporosis, Cushingoid features |
⭐ Calcineurin inhibitors (Tacrolimus, Cyclosporine) are metabolized by CYP3A4; many drug-drug interactions can affect their levels.
Post-Op Complications - Navigating the Aftermath
- Opportunistic Infections: Follow a predictable timeline based on the net state of immunosuppression.
- Metabolic Syndrome: Immunosuppressants often drive new-onset diabetes, hypertension, and hyperlipidemia.
- Renal Insufficiency: A major long-term issue, frequently due to calcineurin inhibitor (tacrolimus) nephrotoxicity.
- Malignancy: Significantly ↑ risk of skin cancer (squamous cell) & Post-Transplant Lymphoproliferative Disorder (PTLD).
⭐ PTLD is a life-threatening B-cell proliferation driven by Epstein-Barr Virus (EBV). Reducing immunosuppression is a key first step in management.
High‑Yield Points - ⚡ Biggest Takeaways
- MELD score is key for allocation, predicting 3-month mortality using bilirubin, INR, creatinine, and sodium.
- Main indications are acute liver failure, decompensated cirrhosis, and HCC within Milan criteria.
- Absolute contraindications include active extrahepatic malignancy, severe cardiopulmonary disease, and active substance abuse.
- Post-transplant immunosuppression typically involves tacrolimus, mycophenolate, and corticosteroids.
- Suspect acute rejection with rising LFTs; confirm with biopsy. Hepatic artery thrombosis is a major vascular complication.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app